Early clinical study of an intermittent schedule for maytansine (NSC-153858)

R. T. Eagan, J. N. Ingle, J. Rubin, S. Frytak, C. G. Moertel

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m 2 on days 1, 3, and 5 (total dose, 2.25 mg/m 2) repeated every 4 weeks is recommended for Phase II trials.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalJournal of the National Cancer Institute
Volume60
Issue number1
StatePublished - 1978

Fingerprint

Maytansine
Colic
Macrolides
Aspartate Aminotransferases
Thrombocytopenia
Nausea
Vomiting
Diarrhea
Appointments and Schedules
Clinical Trials
Liver
Neoplasms
Cardiotoxicity
Clinical Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eagan, R. T., Ingle, J. N., Rubin, J., Frytak, S., & Moertel, C. G. (1978). Early clinical study of an intermittent schedule for maytansine (NSC-153858). Journal of the National Cancer Institute, 60(1), 93-96.

Early clinical study of an intermittent schedule for maytansine (NSC-153858). / Eagan, R. T.; Ingle, J. N.; Rubin, J.; Frytak, S.; Moertel, C. G.

In: Journal of the National Cancer Institute, Vol. 60, No. 1, 1978, p. 93-96.

Research output: Contribution to journalArticle

Eagan, RT, Ingle, JN, Rubin, J, Frytak, S & Moertel, CG 1978, 'Early clinical study of an intermittent schedule for maytansine (NSC-153858)', Journal of the National Cancer Institute, vol. 60, no. 1, pp. 93-96.
Eagan, R. T. ; Ingle, J. N. ; Rubin, J. ; Frytak, S. ; Moertel, C. G. / Early clinical study of an intermittent schedule for maytansine (NSC-153858). In: Journal of the National Cancer Institute. 1978 ; Vol. 60, No. 1. pp. 93-96.
@article{bbb61ec7941d48718ed5f102f55aa9b2,
title = "Early clinical study of an intermittent schedule for maytansine (NSC-153858)",
abstract = "Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m 2 on days 1, 3, and 5 (total dose, 2.25 mg/m 2) repeated every 4 weeks is recommended for Phase II trials.",
author = "Eagan, {R. T.} and Ingle, {J. N.} and J. Rubin and S. Frytak and Moertel, {C. G.}",
year = "1978",
language = "English (US)",
volume = "60",
pages = "93--96",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Early clinical study of an intermittent schedule for maytansine (NSC-153858)

AU - Eagan, R. T.

AU - Ingle, J. N.

AU - Rubin, J.

AU - Frytak, S.

AU - Moertel, C. G.

PY - 1978

Y1 - 1978

N2 - Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m 2 on days 1, 3, and 5 (total dose, 2.25 mg/m 2) repeated every 4 weeks is recommended for Phase II trials.

AB - Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m 2 on days 1, 3, and 5 (total dose, 2.25 mg/m 2) repeated every 4 weeks is recommended for Phase II trials.

UR - http://www.scopus.com/inward/record.url?scp=0018090648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018090648&partnerID=8YFLogxK

M3 - Article

C2 - 628025

AN - SCOPUS:0018090648

VL - 60

SP - 93

EP - 96

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -